José Ramón Azanza

José Ramón Azanza

Auto-generated profile, based on publicly available information

José Ramón Azanza

Clinica Universidad de Navarra, Spain

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
MCMiguel Angel Campanero
Miguel Angel Campanero
MEManuel Escolar
Manuel Escolar
GPGuiomar Perez
Guiomar Perez
EGEmilio Garcia-Quetglas
Emilio Garcia-Quetglas
BSBelen Sadaba
Belen Sadaba
JAJose Ramon Azanza
Jose Ramon Azanza

5 April 2007 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
ASAlex Soriano
Alex Soriano
JGJ. Gómez
J. Gómez
LGL. Gómez
L. Gómez
JAJ.R. Azanza
J.R. Azanza
RPR. Pérez
R. Pérez
JMJ. Mensa
J. Mensa

1 December 2004 in Transplantation Proceedings
Verified
Journal Article
Closed access
BSB. Sádaba
B. Sádaba
MCM.A. Campanero
M.A. Campanero
EQE.G. Quetglas
E.G. Quetglas
JAJ.R. Azanza
J.R. Azanza

17 December 2003 in Journal of Chromatography A
Verified
Journal Article
Closed access
MCMiguel Angel Campanero
Miguel Angel Campanero
EGEmilio Garcı́a-Quetglas
Emilio Garcı́a-Quetglas
BSBelén Sádaba
Belén Sádaba
JAJose Ramón Azanza
Jose Ramón Azanza

5 April 2023 in Revista Española de Quimioterapia
Verified
Journal Article
Open access
JAJosé Ramón Azanza
José Ramón Azanza
JMJosé Mensa
José Mensa
JBJosé Barberán
José Barberán
LVLourdes Vázquez
Lourdes Vázquez
JOJaime Pérez de Oteyza
Jaime Pérez de Oteyza
CGCarlos Dueñas Gutiérrez
Carlos Dueñas Gutiérrez
The administration of antifungals for therapeutic and, especially, prophylactic purposes is virtually a constant in patients requiring hematology-oncology treatment. Any attempt to prevent or treat Aspergillus or Mucor infections requires the administration of some drugs in the azole group, which include voriconazole, posaconazole and isavuconazole, noted for their activity against these pathogens. One very relevant aspect is the potential risk of interaction when associated with one of the antineoplastic drugs used to treat hematologic tumors, with serious complications. In this regard, acalabrutinib, bortezomib, bosutinib, carfilzomib, cyclophosphamide, cyclosporine A, dasatinib, duvelisib, gilteritinib, glasdegib, ibrutinib, imatinib, nilotinib, ponatinib, prednisone, ruxolitinib, tacrolimus, all-transretinoic acid, arsenic trioxide, venetoclax, or any of the vinca alkaloids, are very clear examples of risk, in some cases because their clearance is reduced and in others because of increased risk of QTc prolongation, which is particularly evident when the drug of choice is voriconazole or posaconazole.

26 March 2013 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
BSB. Sádaba
B. Sádaba
AGA. Gómez-Guiu
A. Gómez-Guiu
JAJ. R. Azanza
J. R. Azanza
IOI. Ortega
I. Ortega
RVR. Valiente
R. Valiente